PostEra, a Boston-based biotech company powered by machine learning, has announced an expanded partnership with US pharmaceutical giant Pfizer (NYSE: PFE). The collaboration includes the launch of a new antibody drug conjugate (ADC) program, as well as the expansion of an existing USD 260 million AI Lab collaboration project.
Financial Terms and Incentives
Under the new deal, PostEra will receive USD 12 million upfront and is eligible for additional milestone payments and tiered royalties on any approved products resulting from the collaboration. The agreement is expected to be worth a total of USD 610 million, reflecting the success of their previous cooperation.
Significance of the Expanded Partnership
This expanded partnership highlights the growing role of machine learning and AI in drug development. By combining PostEra’s advanced AI capabilities with Pfizer’s expertise, the collaboration aims to accelerate the discovery and development of innovative therapies, including antibody drug conjugates. This strategic alliance is expected to drive significant advancements in the pharmaceutical industry, potentially leading to more effective treatments for various diseases.-Fineline Info & Tech
